Skip to content

Evaluation of Safety and Efficacy with Treatment by Albuvirtide-Based Antiretroviral Regimen in HIV Post-Exposure Prophylaxis

Evaluation of Safety and Efficacy with Treatment by Albuvirtide-Based Antiretroviral Regimen in HIV Post-Exposure Prophylaxis

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022881
Enrollment
Unknown
Registered
2019-04-29
Start date
2019-05-06
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS

Interventions

Group 1:ABT+DTG
Group 2:ABT+TDF+3TC
Group 3:DTG+TDF+3TC

Sponsors

Chongqing Public Health Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: HIV exposed subjects are required to meet all of the following criteria for enrollment into the study. 1. Males and females, aged >= 18 years; 2. History of HIV exposure: HIV exposure source damages skin (stabbing or cuts, etc.) or it is contaminated with incomplete skin or mucosa; or high-risk sexual behavior with HIV-infected or potential/suspected HIV-infected persons; 3. Receiving the first dose of blocking drug within 72 hours after exposure; 4. HIV antibody negative when exposed; 5. Both male and female subjects and their partners of childbearing potential must agree to contraception; 6. Females of childbearing potential must have a negative urine pregnancy test; 7. Willing and able to participate in all aspects of the study, including use of intravenous medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent.

Exclusion criteria

Exclusion criteria: 1) The exposure time exceeds 72h; 2) Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study; 3) Hepatitis B infection as manifest by the presence of Hepatitis B surface antigen (HBsAg); 4) Any known allergy or antibodies to the study drug or excipients; 5) Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.

Design outcomes

Primary

MeasureTime frame
Proportion of patients taking the uninterrupted HIV post-exposure prophylaxis for 28 days;

Secondary

MeasureTime frame
Incidence of adverse events (AE) and serious adverse events (SAE);Compliance;HIV infection rate after exposure (Day 28);HIV infection rate after exposure (Week 12);

Countries

China

Contacts

Public ContactYaokai Chen

Chongqing Public Health Medical Center

yaokaichen@hotmail.com+86 13638352995

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026